Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count

Authors:

Abstract
(2020). Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leukemia & Lymphoma. Ahead of Print.

This publication has 14 references indexed in Scilit: